Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease ...

With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK charity behind the popular Dry January initiative, found that 30% of men ...

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

The legislation permanently reclassifies fentanyl as a Schedule I drug, meaning it has no accepted medical use and a high ...